Get the Stockscreener App
19.75
8.52%
1.55
After Hours:
19.75
Staar Surgical Co stock is traded at $19.75, with a volume of 3.34M.
It is up +8.52% in the last 24 hours and up +3.19% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
See More
Previous Close:
$18.20
Open:
$18.35
24h Volume:
3.34M
Relative Volume:
2.31
Market Cap:
$974.98M
Revenue:
$230.59M
Net Income/Loss:
$-96.37M
P/E Ratio:
-10.09
EPS:
-1.9571
Net Cash Flow:
$-39.54M
1W Performance:
+21.91%
1M Performance:
+3.19%
6M Performance:
-29.08%
1Y Performance:
+21.76%
1-Day Range:
$18.20
$19.87
1-Week Range:
$16.32
$19.87
52-Week Range:
$14.69
$30.81
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STAA
Staar Surgical Co
|
19.75 | 898.46M | 230.59M | -96.37M | -39.54M | -1.9571 |
|
ISRG
Intuitive Surgical Inc
|
494.02 | 174.76B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.49 | 52.44B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
84.13 | 40.70B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
49.99 | 40.28B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
251.63 | 37.99B | 5.40B | 1.49B | 1.78B | 10.12 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Wedbush | Neutral |
| Jan-16-26 | Resumed | Morgan Stanley | Underweight |
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Eye lens maker STAAR Surgical sets March 3 call on 2025 results, China recovery - Stock Titan
FDA expands age indication for STAAR’s EVO ICL to patients aged 21–60 years - Optometry Times
STAAR Surgical Company (STAA) Stock Analysis: Navigating Growth Amidst a 27.10% Potential Upside - DirectorsTalk Interviews
FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs - Eyes On Eyecare
STAA Gains FDA Nod to Expand EVO ICL Age Indication to 60 Years - Yahoo Finance
FDA Approves Expanded Age Range for STAAR Surgical’s EVO ICL for Vision Correction - VisionMonday.com
Alcon launches TOTAL30 Multifocal for Astigmatism toric contact lens - Eyes On Eyecare
Midday Stock Roundup: Staar Surgical up on FDA approval - Orange County Business Journal
FDA expands age indication for Staar Surgical EVO ICL - MassDevice
Why Is Staar Surgical Stock Gaining Wednesday?Staar Surgical (NASDAQ:STAA) - Benzinga
Staar Surgical Gains Key FDA Approval to Broaden Patient Eligibility - AD HOC NEWS
FDA approved expanded age indication for EVO/EVO+ Visian implantable lenses - TipRanks
STAAR Surgical (STAA) Expands Lens Use with FDA Approval - GuruFocus
FDA expands U.S. age indication for EVO ICL - marketscreener.com
FDA clears STAAR eye lens for ages 21–60, opening option for 8M more - Stock Titan
New Alcon lens helps aging eyes stay in contacts all month - Stock Titan
Credit Industriel ET Commercial Invests $3.26 Million in STAAR Surgical Company $STAA - MarketBeat
3 Low-Volatility Stocks We Find Risky - Finviz
New York Life Investment Management LLC Takes Position in STAAR Surgical Company $STAA - MarketBeat
STAAR Surgical Company (STAA) Stock Analysis: Exploring a 37.81% Potential Upside for Investors - DirectorsTalk Interviews
Alpine Associates Management Inc. Acquires Shares of 913,087 STAAR Surgical Company $STAA - MarketBeat
VIEW Optometry launches to support independent practices - Eyes On Eyecare
STAAR Surgical Company (NASDAQ:STAA) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
212,421 Shares in STAAR Surgical Company $STAA Acquired by Versor Investments LP - MarketBeat
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
STAAR Surgical (NASDAQ:STAA) Given New $19.00 Price Target at Stifel Nicolaus - MarketBeat
Staar Surgical price target lowered to $19 from $28 at Stifel - TipRanks
Leadership watch: Staar Surgical names co-CEOs, ACET adds to Board - Eyes On Eyecare
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns By Investing.com - Investing.com India
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns - Investing.com Nigeria
Staar Surgical CoEnters agreement with Chief Legal Officer Nathaniel SisitskySEC filing - marketscreener.com
STAAR Surgical Company (STAA): A Bull Case Theory - Finviz
Staar Surgical initiated with a Neutral at Wedbush - TipRanks
STAAR Surgical sinks as it plans to terminate sale to Alcon (update) - MSN
Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
STAA Receives Neutral Rating as Wedbush Initiates Coverage | STA - GuruFocus
STAAR names interim co-CEOs amid search for permanent leader - MedTech Dive
STAAR Surgical (NASDAQ:STAA) Now Covered by Wedbush - MarketBeat
STAAR Surgical (STAA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
STAAR Surgical Names Warren Foust and Deborah Andrews Interim Co-CEOs - VisionMonday.com
Why STAAR Surgical (STAA) stock is trading lower today - MSN
Staar Surgical names interim co-CEOs in leadership shift following failed Alcon deal - massdevice.com
Why STAAR Surgical (STAA) Shares Are Down Today - Bitget
Why STAAR Surgical (STAA) Stock Is Trading Lower Today - Finviz
Staar Surgical Appoints Interim Co-CEOs - Orange County Business Journal
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs - PharmiWeb.com
New weekly contact lens offers Canadians 16 hours of daily comfort - stocktitan.net
Staar Surgical appoints Warren Foust & Deborah Andrews interim co-CEOs - marketscreener.com
STAAR Surgical Company Announces Interim Co-CEO Appointments, Effective February 1, 2026 - marketscreener.com
Staar Surgical (STAA) Appoints Interim Co-CEOs as CEO Search Beg - GuruFocus
A month after Alcon deal fell through, Staar Surgical searches for next CEO and names interim leaders - Fierce Biotech
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):